A Review on Potential Drug Delivery System as a Treatment of Intercellular Bacterial Infection
Intracellular bacterial pathogens are hard to treat because of the inability of conventional antimicrobial agents belonging to widely used classes, like aminoglycosides and β-lactams, fluoroquinolones, or macrolides to penetrate, accumulate, or be retained in the mammalian cells. The increasing problem of antibiotic resistance complicates more the treatment of the diseases caused by these agents. In many cases, the increase in therapeutic doses and treatment duration is accompanied by the occurrence of severe side effects. Taking into account the huge financial investment associated with bringing a new antibiotic to the market and the limited lifetime of antibiotics, the design of drug delivery systems to enable the targeting of antibiotics inside the cells, to improve their activity in different intracellular niches at different pH and oxygen concentrations, and to achieve a reduced dosage and frequency of administration could represent a prudent choice. An ideal drug delivery system should possess several properties, such as antimicrobial activity, biodegradability, and biocompatibility, making it suitable for use in biomedical and pharmaceutical formulations. This approach allow reviving old antibiotics rendered useless by resistance or toxicity, rescuing the last line therapy antibiotics by increasing the therapeutic index, widening the antimicrobial spectrum of antibiotics scaffolds that failed due to membrane permeability problems, and thus reducing the gap between increasingly drug-resistant pathogens and the development of new antibiotics. Different improved drug carriers have been developed for treating intracellular pathogens, including antibiotics loaded into liposomes, microspheres, polymeric carriers, and nanoplexes. The purpose of this chapter is to present the limitations of each class of antibiotics in targeting intracellular pathogens and the main research directions for the development of drug delivery systems for the intracellular release of antibiotics.
Alonso A and Garcia-del Portillo F. Hijacking of eukaryotic functions by intracellular bacterial pathogens. Int Microbiol, 2004;7(3), 181-191.
Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies: Workshop Summary. Washington, DC: The National Academies Press. 2010, 496.
Baltch AL, Bopp LH, Smith RP, Michelsen PB and Ritz WJ. Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J Antimicrob Chemother, 2005; 56(1):104-109.
Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM and Van Bambeke F. Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages. Antimicrob. Agents Chemother. 2006, 50(3):841-851.
Barnewall RE, Rikihisa Y and Lee EH. Ehrlichia chaffeensis inclusions are early endosomes which selectively accumulate transferrin receptor. Infect Immun, 1997; 65(4):1455-1461.
Beron W, Alvarez-Dominguez C, Mayorga L and Stahl PD. Membrane trafficking along the phagocytic pathway. Trends in Cell Biology, 1995; 5(3):100-104.
Bonazzi M and Cossart P. Bacterial entry into cells: a role for the endocytic machinery. FEBS Lett, 2006; 580(12): 2962-2967.
Butts JD. Intracellular concentrations of antibacterial agents and related clinical implications. Clin Pharmacokinet, 1994;27(1):63-84.
Carlier MB, Scorneaux B, Zenebergh A, Desnottes JF and Tulkens PM. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother,1990, 26:27- 39.
Carryn S, Van Bambeke F, Mingeot-Leclercq MP and Tulkens PM. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta- lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother, 2002; 46(7): 2095-2103.
Clemens DL, Lee BY and Horwitz MA. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect Immun, 2004;72(6): 3204-3217.
Cordeiro C, Wiseman DJ, Lutwyche P, et al. Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar Typhimurium intracellular infection model. Antimicrob Agents Chemother, 2000;44(3):533–539.
Cuffini AM, Tullio V, Mandras N, Roana J, Banche G and Carlone NA. The leading role of antimicrobial agents in modulating the binomial host-microorganism Curr. Med. Chem.-Anti-Infective Agents, 2004;3:1-13.
Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta. 1997;1334(2-3):161-172.
Desjardins M, Huber LA, Parton RG and Griffiths G. Biogenesis of phagolysosomes proceeds through a sequential series of interactions with the endocytic apparatus. J. Cell Biol. 1994; 124(5): 677-688.
Desjardins M. Biogenesis of phagolysosomes: the kiss and run hypothesis. Trends in Cell Biology, 1995; 5(5): 183-186.
Dijkstra J, van Galen WJM, Regts J, et al. Uptake and processing of liposomal phospholipids by Kuppfer cells in vitro. Eur J Biochem. 1985;148(2):391-397.
Domingo S, Gastearena I, Diaz R and Gamazo C. Significance of environmental conditions (pH and serum) on the in vitro potency of azithromycin against Brucella melitensis. J Chemother,1995; 7 (4): 29-31.
Drevets DA, Canono BP, Leenen PJ and Campbell PA. Gentamicin kills intracellular Listeria monocytogenes. Infect Immun, 1994; 62(6):2222- 2228.
Ghigo E, Capo C, Tung CH, Raoult D, Gorvel JP and Mege JL. Coxiella burnetii survival in THP-1 monocytes involves the impairment of phagosome maturation: IFN-gamma mediates its restoration and bacterial killing. J Immunol, 2002; 169(8):4488-4495.
Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995;13(12):527-537.
Gregoriadis G. The carrier potential of liposomes in biology and medicine. N Engl J Med. 1976;295(14):765- 770.
Hackam DJ, Rotstein OD, Zhang W, Gruenheid S, Gros P and Grinstein S. Host resistance to intracellular infection: mutation of natural resistance-associated macrophage protein 1 (Nramp1) impairs phagosomal acidification. J Exp Med, 1998; 188(2):351-364.
Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006;13(6):399-409.
Hashim S, Mukherjee K, Raje M, Basu SK and Mukhopadhyay A. Live Salmonella Modulate Expression of Rab Proteins to Persist in a Specialized Compartment and Escape Transport to Lysosomes. J. Biol. Chem., 2000; 275(21):16281-16288.
Heinzen RA, Scidmore MA, Rockey DD and Hackstadt T. Differential interaction with endocytic and exocytic pathways distinguish parasitophorous vacuoles of Coxiella burnetii and Chlamydia trachomatis. Infect Immun, 1996; 64(3): 796-809.
Hu CM, Kaushal S, Cao HST, et al. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm. 2010;7(3):914-920.
Huynh NT, Passirani C, Saulnier P, et al. Lipid nanocapsules: a new platform for nanomedicines. Int J Pharm. 2009;379(2):201-209.
Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 2000; 21(23): 2475- 2490.
Joralemon MJ, McRae S, Emrick T. PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Comm. 2010;46(9):1377-1393.
Gilbert P, Collier PJ, Brown MRW. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother. 1990;34(10):1865-1868.
Goldberg MB and Theriot JA. Shigella flexneri surface protein IcsA is sufficient to direct actin-based motility. Proc Natl Acad Sci USA,1995; 92(14) :6572- 6576.
Gregoradis G. Liposome preparation and related techniques. In: Gregoriadis G, editor. Liposome Technology. Boca Raton: CRC Press; 1993. 1-63p.
Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med, 1976; 295(13): 704- 710.
Joshi AD, Sturgill-Koszycki S and Swanson MS. Evidence that Dot-dependent and independent factors isolate the Legionella pneumophila phagosome from the endocytic network in mouse macrophages. Cell Microbiol, 2001;3(2): 99-114.
Jung SK, Lim DH, Jung SH, et al. Amphotercin B- entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur J Pharm Sci. 2009;37(3- 4):313-320.
Kohane DS, Tse JY, Yeo Y, et al. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mater Res. 2006;77(2):351-361.
Krieger J, Childs S, Klimberg I. UTI treatment using liposomal amika in Berlin. Clinical Microbiology. 1999;5(Suppl 3):136-144.
Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B, A. Golda A, A. Maciag-Gudowska A, K. Brix K, L. Shaw L, T. Foster T and J. Potempa J. A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS One, 2008; 3(1), e1409.
Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev, 2000; 13(4): 615-650.
Lasic DD. Novel applications of liposomes. Trends Biotechnol, 1998;16(7):307-321.
Manson N, Thies C and Cicero TJ. In vivo and in vitro evaluation of a microencapsulated narcotic antagonist. J. Pharm. Sci., 1976; 65: 51-59.
Martel S. Disadvantage of nanomedicine. Int J Nanomedicine, 2009; 50:1– 5.
Medina C, Rahme K, Arcy DM, et al. Poloxamer mixed micelles for delivery of gambogic. Int J Nanomedicine, 1996; 10:407-409
Mingeot-Leclercq MP and Tulkens PM. Aminoglycosides: Nephrotoxicity. Antimicrob. Agents Chemother,1999; 43(5): 1003- 1012.
Mingeot-Leclercq MP, Glupczynski Y and Tulkens PM. Aminoglycosides: Activity and Resistance. Antimicrob. Agents Chemother., 1999; 43(4) :727- 737.
Mundargi RC, Babu VR, Rangaswamy V, Patel P and Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J Control Release, 2008; 125(3): 193-209.
Nguyen HA, Grellet J, Paillard D, Dubois V, Quentin C and Saux MC. Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model. J Antimicrob Chemother, 2006; 57(5): 883-890.
Portnoy DA, Auerbuch V and Glomski IJ. The cell biology of Listeria monocytogenes infection: the intersection of bacterial pathogenesis and cell- mediated immunity. J Cell Biol, 2002; 158(3) :409- 414.
Prior S, Gander B, Blarer N, Merkle HP, Subira ML, Irache JM and Gamazo C. In vitro phagocytosis and monocytemacrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci, 2002; 15(2):197-207.
Roy CR and Tilney LG. The road less traveled: transport of Legionella to the endoplasmic reticulum. J Cell Biol,2002; 158(3):415-419.
Schiffelers RM, Storm G, Bakker-Woudenberg IA. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm Res., 2001;18(6):780– 787.
Scidmore MA, Fischer ER and Hackstadt T. Restricted fusion of Chlamydia trachomatis vesicles with endocytic compartments during the initial stages of infection. Infect Immun, 2003;71(2):973-984.
Seleem MN, Munusamy P, Ranjan A, et al. Silica- antibiotic hybrid nanoparticles for targeting intracellular pathogens. Antimicrob Agents Chemother. 2009; 53(10):4270-4274.
Seral C, Van Bambeke F and Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother, 2003; 47(7):2283- 2292.
Sessa G, Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res. 1968;9(3):310-318.
Sihorkar V, Vyas SP. Biofilm consortia on biomedical and biological surfaces: delivery and targeting strategies. Pharm Res. 2001;18(9):1247-1254.
Sturgill-Koszycki S, Schaible UE and Russell DG. Mycobacterium-containing phagosomes are accessible to early endosomes and reflect a transitional state in normal phagosome biogenesis. EMBO J, 1996; 15(24): 6960-6968.
Suzuki T and Sasakawa C. Molecular basis of the intracellular spreading of Shigella. Infect Immun, 2001; 69(10) :5959-5966.
Swenson CE, Popescu MC, Ginsberg RS. Preparation and use of liposomes in the treatment of microbial infections. Crit Rev Microbiol., 1988;15(Suppl 1):S1- S31.
Tewers F, Boury F and Benoit JP. Biodegradable Microspheres: Advances in Production Technology. In Microencapsulation: Methods and Industrial Applications. Ed S. Benita. Marcel Dekker, New York (2006)
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
Tsukano H, Kura F, Inoue S, Sato S, Izumiya H, Yasuda T and Watanabe H. Yersinia pseudotuberculosis blocks the phagosomal acidification of B10.A mouse macrophages through the inhibition of vacuolar H (+)-ATPase activity. Microb Pathog, 1999; 27(4): 253-263.
Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep. 2002;22(2):129-150.
Van Bambeke F, Michot JM and Tulkens PM. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother, 2003; 51(5):1067-1077.
Van den Broek PJ. Antimicrobial drugs, microorganisms, and phagocytes. Rev Infect Dis, 1989; 11(2):213-245.
Van Ooij C, Kalman L, van I, Nishijima M, Hanada K, Mostov K and Engel JN. Host cell-derived sphingolipids are required for the intracellular growth of Chlamydia trachomatis. Cell Microbiol, 2000; 2(6):627-637.
Wakiyama N, Juni K and Nakano M. Preparation and evaluation in vitro and in vivo of polylactic acid microspheres containing dibucaine. Chem Pharm Bull (Tokyo), 1982; 30(10):3719-3727.
Copyright (c) 2020 Madhushreeta Manna, Arijit Shil
This work is licensed under a Creative Commons Attribution 4.0 International License.